01March

Change in Novo Nordisk Executive Management ... Read more

28February

Novo Nordisk files for regulatory approval of once-weekly semaglutide for the tr ... Read more

20March

Novo Nordisk A/S - Share repurchase programme ... Read more

13March

Novo Nordisk A/S - Share repurchase programme ... Read more

06March

Novo Nordisk A/S - Share repurchase programme ... Read more

01March

Change in Novo Nordisk Executive Management ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations

 

Novo Nordisk News


Robert Wood Johnson Foundation awards million-dollar research grant for the study of healthier cities

2 March - The Robert Wood Johnson Foundation has awarded a three-year, 2.4 million USD grant to The University of Texas Health Science Center at Houston (UTHealth) School of Public Health to create the Healthy Cities Research Hub focusing on the social and environmental conditions that impact health in urban settings throughout North America. The research hub will focus on extracting and translating the learnings from community-led efforts by 'Cities Changing Diabetes’ .

“When we initiated Cities Changing Diabetes, our goal was to join forces with cities and community stakeholders to understand and address the urban diabetes challenge — globally and locally,” said Niels Lund, vice president for Health Advocacy, Novo Nordisk.

“This collaboration with the Robert Wood Johnson Foundation and UTHealth is an important step forward in this effort and we're proud and honoured to be part of it.”

Read more about the Robert Wood Johnson Foundation and Cities Changing Diabetes

 



The Novo Nordisk Research Centre Oxford

Novo Nordisk and University of Oxford entering collaboration on type 2 diabetes with GBP 115m investment

30 January - University of Oxford and Novo Nordisk has announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. Sir John Bell, Regius Professor of Medicine, University of Oxford, said: “We see the collaboration with Novo Nordisk as an outstanding opportunity to mix competence embedded at our campus with Novo Nordisk’s groundbreaking research and results in diabetes. This collaboration underlines the importance of shared research and cutting-edge science across boundaries". The Novo Nordisk Research Centre Oxford will employ up to 100 Novo Nordisk researchers.

Read the press release

 


Novo Nordisk and Glooko partner to develop digital health solutions 

Novo Nordisk and Glooko will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. Read all the details


The hidden talents

Imagine that you perceive the noise level in the canteen as 100 times louder, and that even minor changes in your daily life cause you to lose your overview. Such is life for 28-year-old Louise Wille, who has Asperger’s and ADHD.

Read the whole story

Louise Wille

Going 100% renewable

Our production site in Tianjin rose to the challenge of moving away from coal-based energy and reached its goal of using 100% renewable power for all its production - made possible through the purchase of green energy from a wind farm in Leo’s hometown.

Read the story from Leo's perspective

Going 100% renewable in China

Sarah Ahmed from Ethopia has type 1 diabetes

Novo Nordisk committed to guarantee access to insulin

22 September - Access to reliable and affordable supplies of insulin is a challenge for many in the poorest nations in the world. Lars Rebien Sørensen has pledged to extend the current programme from 2001 and expand Novo Nordisk's commitment to supply human insulin at fixed low prices to the Least Developed Countries and low-income nations; the programme will now be extended to cover selected organisations providing relief in humanitarian situations.

Read all the details about Novo Nordisk's programme on access to insulin

The diabetes challenge - get an overview of Novo Nordisk's commitment 


Calendar

Annual General Meeting
23MarchCopenhagen, Denmark

Annual report 2016

Read about former CEO Lars Rebien Sørensen's reflections on 2016 and present CEO Lars Fruergaard Jørgensen's thoughts about the road ahead for Novo Nordisk and much more in the Annual Report 2016


Our carbon footprint

How can Novo Nordisk play a role in offering solutions that are good for people’s health and the planet? Read what CEO Lars Fruergaard Jørgensen says and how we can take carbon emissions to the product level.


An exceptional patient entrepreneur!

Winner of Lyfebulb award

Dec '16 - Patient entrepreneur Brianna Wolin was selected as winner of the Lyfebulb-Novo Nordisk Innovation Award: 'Find Your Ditto' - a mobile platform which connects patients living with the same chronic illness for on-demand, in-person peer support.

Read more about the Lyfebulb-Novo Nordisk partnership


Novo Nordisk in brief


Get an instant impression of what Novo Nordisk is about, see the numbers and read about partnership activities that drive change. 

Download Novo Nordisk backgrounder 


Novo Nordisk Stories

Views on obesity

The view on obesity is slowly changing, but there are still many myths about the disease that all contribute to creating barriers for proper treatment.

Read the story

Theme: Innovation